Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
作者更正：辅助治疗三阴性乳腺癌残余患者：纳武利尤单抗、卡培他滨或二者联合治疗：OXEL随机II期研究
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-024-48359-1
Lynce, Filipa; Mainor, Candace; Donahue, Renee N; Geng, Xue; Jones, Greg; Schlam, Ilana; Wang, Hongkun; Toney, Nicole J; Jochems, Caroline; Schlom, Jeffrey; Zeck, Jay; Gallagher, Christopher; Nanda, Rita; Graham, Deena; Stringer-Reasor, Erica M; Denduluri, Neelima; Collins, Julie; Chitalia, Ami; Tiwari, Shruti; Nunes, Raquel; Kaltman, Rebecca; Khoury, Katia; Gatti-Mays, Margaret; Tarantino, Paolo; Tolaney, Sara M; Swain, Sandra M; Pohlmann, Paula; Parsons, Heather A; Isaacs, Claudine
